MCT8 - AHDS Foundation
Ongoing Medical Trials
Trial 1:
Official Title: Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial II
Description: The current Trial (Triac Trial II) will investigate if Triac treatment in AHDS patients improves the neurocognitive phenotype.
Primary Purpose: Treatment
Estimated Study Start Date : June 2018
Estimated Study Completion Date : December 2022
Location: Erasmus Medical Center, Rotterdam
Principal Investigator: Dr. W.E. Wisser, Erasmus Medical Center
Recruitment Status : Now recruiting
Web page: https://clinicaltrials.gov/ct2/show/NCT02396459
Trial 2: